PrEP Implementation in the CEE Region: What are the Successes, What are the Barriers? Prof. Milosz Parczewski

Central and Eastern European Meeting on Viral Hepatitis and HIV 2020

Debate: Do Integrase Inhibitors and/or TAF Lead to Weight Gain? Con Standpoint - Jürgen Rockstroh

Central and Eastern European Meeting on Viral Hepatitis and HIV 2020

Long-Acting Therapies: Which Patients Will Benefit Most? - Dr. Sharon Walmsley

Central and Eastern European Meeting on Viral Hepatitis and HIV 2020

Gilleece, Yvonne - The Management of Hepatitis in Pregnancy

Central and Eastern European Meeting on Viral Hepatitis and HIV 2020

Abstract #5 - Quality of lives of PLWHA from Baylor Clinic in Constanta, Romania decreased during the COVID-19 pandemic Ana-Maria Schweitzer, Baylor Black Sea Foundation, Romania

Central and Eastern European Meeting on Viral Hepatitis and HIV 2020

Abstract #4 - Determination of drug resistance of hepatitis C virus to NS5A protein inhibitors as a new approach to personalized medicine - Elena Gasich, Belarus

Central and Eastern European Meeting on Viral Hepatitis and HIV 2020

Abstract #3 - Evidence of experience in Community-based HCV Treatment among HIV/HCV Co-infected PWIDs in Ukraine - Zahedul Islam, Alliance Public Health, Ukraine

Central and Eastern European Meeting on Viral Hepatitis and HIV 2020

Central and Eastern European Meeting on Viral Hepatitis and HIV 2020

Abstract #2 - A pilot study of the acceptability and feasibility of HCV self-testing among key populations in Georgia - Sonjelle Shilton, FIND, Switzerland

Central and Eastern European Meeting on Viral Hepatitis and HIV 2020

Abstract # 1 - Characteristics of women diagnosed with HIV in the WHO European Region and predictors of late diagnosis - Otilia Mårdh, ECDC, Sweden

Central and Eastern European Meeting on Viral Hepatitis and HIV 2020

The Acute HCV Epidemic in MSM: What Have We Learned Thus Far? - Christoph Boesecke

Central and Eastern European Meeting on Viral Hepatitis and HIV 2020

Managing Highly Treatment-Experienced Patients: What are the New Drug Options - Prof. Anca Streinu Cercel

Central and Eastern European Meeting on Viral Hepatitis and HIV 2020

Management of Viral Hepatitis During Pregnancy - Dr. Yvonne Gilleece

Central and Eastern European Meeting on Viral Hepatitis and HIV 2020

ART in Women: Which Drugs are Safe and What are the Challenges? - Dr. Annette Haberl

Central and Eastern European Meeting on Viral Hepatitis and HIV 2020

PrEP Implementation in the CEE Region - Prof. Milosz Parczewski

Central and Eastern European Meeting on Viral Hepatitis and HIV 2020

2020: Have We Reached the 90-90-90 Targets? - Teymur Noori

Central and Eastern European Meeting on Viral Hepatitis and HIV 2020

Abstract Book - CEE Meeting on Viral Hepatitis and HIV 2020

Central and Eastern European Meeting on Viral Hepatitis and HIV 2020

Abstract Book - European Meeting on HIV & Hepatitis 2020

European Meeting on HIV & Hepatitis 2020

Young Russian Women With HIV/HCV Co-Infection: Clinical Status and Effective Medical Care Options.

Central and Eastern European Meeting on Viral Hepatitis and HIV 2020

Recent Insights Into Risk Factors for HBV Vertical Transmission

Central and Eastern European Meeting on Viral Hepatitis and HIV 2020

Hepatotoxicity Among HIV-Positive Ukrainian Patients Receiving Different Regimens of ART

Central and Eastern European Meeting on Viral Hepatitis and HIV 2020

Influence of Directly Acting Antiviral Drugs Therapy of Hepatitis C on the Course of HIV Infection in Patients With HIV and Hepatitis C Co-Infection

Central and Eastern European Meeting on Viral Hepatitis and HIV 2020

Seroprevalence of Hepatitis E Virus in Rural Residents in Northern Vietnam

Central and Eastern European Meeting on Viral Hepatitis and HIV 2020

Recurrent Visceral Leishmaniasis in Immunocompromised Patient With Liver Cirrhosis

Central and Eastern European Meeting on Viral Hepatitis and HIV 2020